Rabeprazole Sodium - CAS 117976-90-6
Catalog number: 117976-90-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C18H20N3NaO3S
Molecular Weight:
381.42
COA:
Inquire
Targets:
Proton Pump
Description:
The sodium salt form of Rabeprazole which is a partially reversible inhibitor of gastric proton pump and could be used in the treatment of sorts of gastrointestinal disease especially peptic ulcer.
Purity:
95%
Appearance:
white or off white crystalline powder
Synonyms:
sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide;RABEPRAZOLESODIUM;117976-90-6;Pariet;Aciphex
Solubility:
DMSO 48 mg/mL
Storage:
-20ºC Freeze
MSDS:
Inquire
Application:
The sodium salt form of Rabeprazole which is a partially reversible inhibitor of gastric proton pump and could be used in the treatment of sorts of gastrointestinal disease especially peptic ulcer.
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Quantity:
Grams-Kilos
Boiling Point:
603.9ºC at 760 mmHg
Melting Point:
140-141ºC dec.
Density:
0.45~0.55 g/ml
InChIKey:
KRCQSTCYZUOBHN-UHFFFAOYSA-N
InChI:
InChI=1S/C18H20N3O3S.Na/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18;/h3-4,6-9H,5,10-12H2,1-2H3;/q-1;+1
Canonical SMILES:
CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3[N-]2)OCCCOC.[Na+]
1.[Clinical aspects of using pariet in treating chronic pancreatitis].
Sablin OA;Ratnikov VA;Butenko EV;Pakhomova IG Eksp Klin Gastroenterol. 2002;(5):73-6, 129.
Three groups of patients were studied with the purpose of assessing the efficiency of the application of Pariet in the complex treatment of chronic pancreatitis. The first group (16 people) underwent conventional treatment (spasmolytics, enzymes, disintoxication therapy). In addition to conventional treatment, the second (22 people) and third (21 people) groups were administered Pariet (rabeprazole), 20 mg per day, or Quamatel (famotidine), 40 mg per day, respectively. The intragastric and intraduodenal pH was higher against the background of the treatment with Pariet than against the background of the application of Quamatel even within the first hours and days of treatment. A faster pain relief was observed in the second group of patients (p 0.05) than in the third one. According to the MRI data, the seven-day Pariet treatment of patients with chronic pancreatitis was accompanied by a reduction of the pancreas size, the diameter of the main pancreatic duct and the pancreatic edema. Thus, the application of Pariet in the complex treatment of chronic pancreatitis promotes a faster and more efficient pain relief and reduction of pancreatic edemas, as compared to the Quamatel therapy.
2.A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori.
Hirai M;Azuma T;Ito S;Kato T;Kohli Y J Gastroenterol. 1995 Aug;30(4):461-4.
Helicobacter pylori infection is causally related to atrophic gastritis, and it may also be associated with peptic ulcer and gastric carcinoma. Eradication of H.pylori is recommended in patients with such diseases, especially in those with peptic ulcer. A new potent proton pump inhibitor, E3810, had an antibacterial effect on H. pylori, as has been reported for omeprazole and lansoprazole, two other proton pump inhibitors. The minimum inhibitory concentration of E3810 was 1.57-3.13 micrograms/ml, lower than that of omeprazole or lansoprazole. To clarify the mechanism of the antibacterial effect of E3810, we analyzed the characteristics of E3810 binding to H. pylori. Scatchard plot analysis of this binding showed a curvilinear profile, indicating the presence of several molecules with different affinities to E3810 on H. pylori. The binding capacity of E3810 to H. pylori was calculated to be about 2 x 10(6) sites/cell. These results suggested that E3810 has an antibacterial effect against H. pylori and that the effect may be mediated through direct binding to H. pylori.
3.Identification and synthesis of potential impurities of rabeprazole sodium.
Pingili RR;Jambula MR;Ganta MR;Ghanta MR;Sajja E;Sundaram V;Boluggdu VB Pharmazie. 2005 Nov;60(11):814-8.
Rabeprazole sodium (1, Achiphex) is a gastric proton pump inhibitor. It causes dose-dependent inhibition of acid secretion and is useful as an anti-ulcer agent. In the process for the preparation of 1, two potential unknown impurities were identified in HPLC at levels ranging from 0.05-0.8%. Based on mass spectral data vide LC-MS, the two impurities were characterized as 2-{[(4-chloro-3-methyl-2-pyridinyl) methyl] sulfinyl}-1H-bezimidazole (2, chloro analogue of rabeprazole) and 2-[{(4-methoxy-3-methyl-2-pyridinyl)methyl}sulfinyl]-1H-benzimidazole (3, methoxy analogue of rabeprazole). The structures were unambiguously established by independently synthesizing them and co-injecting in HPLC. To our knowledge, the compounds 2 and 3 have not been reported as process impurities elsewhere.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Proton Pump Products


CAS 161796-84-5 Esomeprazole potassium

Esomeprazole potassium
(CAS: 161796-84-5)

Esomeprazole potassium is a proton pump inhibitor which acts as selective inhibiton of H+/K+-ATPase. With antiulcerative effects in vivo, it treats or ameliorat...

CAS 102625-70-7 Pantoprazole

Pantoprazole
(CAS: 102625-70-7)

Pantoprazole, an irreversible protonpump inhibitor, inhibits the final step of the production ofgastric acid by binding to the sites of H+/K+ ATPase system in g...

CAS 138786-67-1 Pantoprazole sodium

Pantoprazole sodium
(CAS: 138786-67-1)

The sodium salt form of Pantoprazole, a gastic proton pump inhibitor, could be used in the treatment of ulceration and some diseases induced by gastroesophageal...

CAS 103577-45-3 Lansoprazole.

Lansoprazole.
(CAS: 103577-45-3)

Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.

CAS 117976-89-3 Rabeprazole

Rabeprazole
(CAS: 117976-89-3)

Rabeprazole, a partially reversible inhibitor of gastric proton pump, could be used in the treatment of sorts of gastrointestinal disease especially peptic ulce...

Lansoprazole sodium
(CAS: 226904-00-3)

Lansoprazole sodium is the sodium salt form of Lansoprazole. Lansoprazole, a substituted benzimidizole, is proton pump inhibitor, is a proton pump inhibitor whi...

CAS 117976-90-6 Rabeprazole Sodium

Rabeprazole Sodium
(CAS: 117976-90-6)

The sodium salt form of Rabeprazole which is a partially reversible inhibitor of gastric proton pump and could be used in the treatment of sorts of gastrointest...

CAS 261944-46-1 Soraprazan

Soraprazan
(CAS: 261944-46-1)

Soraprazan, also known as BY359, is a reversible, and fast-acting inhibitor of gastric H+/K+ ATPase, used as anti-secretory drug.

Chemical Structure

CAS 117976-90-6 Rabeprazole Sodium

Quick Inquiry

Verification code

Featured Items